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Death among tuberculosis patients is one of the major reasons for non-attainment of 85% treatment success target
set by World Health Organization. In this short paper, we evaluated whether the overall mortality rate in pulmonary
tuberculosis is being affected by other comorbid conditions. All new smear positive pulmonary tuberculosis patients
(N =336), who started their treatment at the chest clinic of the Penang General Hospital, between March 2010 and
February 2011, were followed-up until December 2011. Tuberculosis treatment outcomes were reported according
to six treatment outcome categories recommended by World Health Organization. The outcome category ‘died’
was defined as ‘a patient who died due to tuberculosis or other cause during tuberculosis treatment’. Our findings
showed that out of 336 smear positive pulmonary tuberculosis patients, 59 (17.6%) died during treatment (mortality
rate = 1.003 cases per 1000 person-days of follow-up).
Among the deceased patients, the mean age was 55.8 years (SD =16.17) and 49 were male. According to the
mortality review forms, 29 deaths were tuberculosis-related, while the remaining 30 patients died due to reasons
other than tuberculosis. Cerebrovascular accident (n =7), septicaemia shock (n =4) and acute coronary syndrome
(n =4) were the most common non-tuberculosis related reasons for mortality in the patients. If the 30 patients,
for whom tuberculosis was incidental to death, are excluded from the final cohort, the proportion of patients in
the ‘died’ outcome category could be reduced to 9.5%. The treatment outcome criterion (i.e., died) set by World
Health Organization has limitations. Therefore, it requires improvement for more objective evaluation of the performance
of the National Tuberculosis Program.Background
Outcomes of tuberculosis (TB) treatment are reported
in line with six outcome categories (i.e., cured, treatment
completed, treatment failure, defaulter, died and trans-
ferred out) recommended by World Health Organization
(WHO) [1]. Cured and treatment completed are further
categorized as successful treatment outcomes, while the
latter four represent unsuccessful treatment outcomes
[2-4]. The National Tuberculosis Program (NTP) of every
country identifies the key areas for improvement. How-
ever, appropriate corrective actions are sometimes futile
due to reasons which are beyond the program’s control
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unless otherwise stated.According to the standard guidelines [1], a person
who dies due to any reason during TB treatment is in-
cluded in the ‘died’ category. From this definition, it is
evident that even patients for whom TB is incidental to
death rather than causal should also be classified in the
‘died’ category of treatment outcomes. For example, if a
TB patient dies of cancer during TB treatment, he or
she should be declared as died due to TB. In such a case,
even if the NTP staff takes timely and appropriate ac-
tions, these deaths are not preventable.
Most of the earlier studies on treatment outcome of TB
explained patients’ death as one of the major causes of non-
attainment of the 85% target treatment success rate [5-7]. In
this paper, we evaluated whether the overall mortality rate in
the patients with pulmonary tuberculosis is being affected
by the other comorbid conditions (Note: The findings pre-
sented in this commentary are part of our previously pub-
lished primary data [7] for which the publication approval. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primary causes of death in the patients
Causes of death Patients n (%)
Tuberculosis 29 (49.2)
Non-tuberculosis 30 (50.8)
Cerebrovascular accident 7 (11.9)
Septicemia shock 4 (6.8)
Acute coronary syndrome 4 (6.8)
Pulmonary embolism 2 (3.4)
Advanced retroviral disease 2 (3.4)
Acute exacerbation of COPD* 2 (3.4)
Other 9 (15.3)
Total 59
*COPD: Chronic obstructive pulmonary disease.
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Malaysia). The study was approved by the Medical Research
Ethics Committee (MERC), Ministry of Health, Malaysia
(Registration ID: NMRR-10-77-5099; MERC reference: dim.
KKM/NIHSEC/08/08/04P10-69).
Methods and key findings
All new smear positive PTB patients who received stan-
dardized anti-TB therapy [1] at the chest clinic of the Pen-
ang General Hospital, Malaysia, between March 2010 and
February 2011, were followed-up until December 2011. A
detailed description of the study setting has been pub-
lished [7]. Medical charts and TB notification forms of the
patients were reviewed to obtain socio-demographic and
clinical data. Treatment outcomes of the patients were re-
ported according to six outcome categories as stipulated
in the WHO guidelines. The treatment outcome category
‘died’ was defined as ‘a patient who died due to TB or
other cause during TB treatment’ [1]. A mortality review
panel which comprised of the medical doctors including
chest physicians evaluated the cause of the patient’s
death. The decision, whether the patient died due to
TB or other reasons was based on available laboratory
data, post mortem reports and/or clinical judgment of
the medical doctors.
The mortality rate by cause in our cohort was calcu-
lated by dividing the number of deaths by person-days at
risk calculated from the time treatment initiated until
the death or end of the treatment [8].
Out of 336 patients registered during the study period
[7], 59 (17.6%) died during their TB treatment (mortality
rate = 1.003 cases per 1000 person-days of follow-up).
Among the deceased patients, the mean age was 55.80 years
(SD =16.17), 49 were male, 41 were married, 28 were dia-
betics, 31 were alcoholics, 39 were smokers, eight were
drug abusers and four were positive for Human Immuno-
deficiency Virus (HIV). Thirty-five patients died within the
first month, whereas eight, nine and seven patients died
during the second, fourth and sixth month of their TB
treatment, respectively. Only four patients died at home,
whereas the remaining 55 patients died at the hospital.
According to the mortality review forms, which were
completed by a panel of physicians including a senior
chest consultant, 30 out of 59 patients died due to rea-
sons other than TB (Table 1).
In this study, the proportion of deceased patients
(17.6%) was similar to that reported in some of the earl-
ier studies from the United States and Western Pacific
Region [9-11]. Two European studies reported that a
higher death rate among TB patients was one of the
major reasons for not meeting the 85% TB treatment
success target [5,6]. In our study, besides expected de-
fault, transfer out and treatment failure rates, the death
rate of more than 15% is alone responsible for not meetingthe success target of 85%. However, if the 30 patients, for
whom TB was incidental to death, are removed from final
analysis, the death rate could be reduced to 9.5% (29/306;
mortality rate = 0.493 cases per 1000 person-days of
follow-up).
Certainly, these findings will not only allow the NTP
managers to have a more objective evaluation of the
NTP, but also increase the overall treatment success rate
in a given cohort. A Russian study also stated that using
such deaths, in which TB is not the actual cause of
death, as an indicator of NTP’s performance might be
misleading, and these deaths might not have been pre-
vented even with improvements in the TB services [8].
In a similar fashion, a UK study demonstrated that it is
unreasonable to consider such deaths as an unsuccessful
treatment outcome of TB [12].
Of course, one might think that if 30 patients, for
whom TB was incidental to death, cannot be placed in
the ‘died’ outcome category of TB treatment outcomes,
then they should be classified somewhere. Unfortunately,
the current TB treatment outcome categories are unable
to accommodate such patients separately. However, the
UK modified criteria for monitoring TB clinical out-
comes classify such patients in the successful treatment
outcome category [12]. Classifying the treatment out-
come of such patients as treatment success may be con-
troversial as these patients died, which is not the target
of any treatment modality.
Conclusion
The tuberculosis treatment outcome criterion (i.e., died)
set by the WHO has limitations, and requires improve-
ments for a more objective evaluation of the perform-
ance of the NTP. We suggest that TB patients for whom
TB is not the actual cause of death should be catego-
rized in a separate outcome category, possibly ‘died not
due to tuberculosis’. It is further suggested that such pa-
tients should neither be categorized in the successful
Atif et al. Journal of Pharmaceutical Policy and Practice 2014, 7:16 Page 3 of 3
http://www.joppp.org/content/7/1/16treatment outcome category nor in the unsuccessful
treatment outcome category.
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